International Scholarly Research Notices

Clinical Study

In Crohn's Disease, Anti-TNF- Treatment Changes the Balance between Mucosal IL-17, FOXP3, and CD4 Cells

Table 2

mRNA expression of L-17, IL-23, FOXP3, IFN- and TNF- in ileal and colonic biopsy samples taken before (0) and 3 months after the beginning of anti-TNF- treatment. Median (range) mRNA levels are expressed as relative units in relation to in-house calibrator (phytohemagglutinin-stimulated peripheral blood monocytes). Asterix: statistically significant differences between patients and control subjects.


		0 month	3 months	Controls


Ileum	IL-17	128.0 (30–325)	67.5 (30–615)	30.0 (30–419)
	IL-23	373.0 (322–804)^*	444.5 (235–542)^*	225.0 (153–706)
	FOXP3	611.0 (15–792)^*	104.5 (15–891)^*	20.5 (15–220)
	IFN-	19.6 (8.6–230)^***	14.0 (1.00–37.6)^*	1.0 (1.0–6.0)
	TNF-	38.7 (8.6–206.6)	43.7 (10.2–249.9)	—

Colon	IL-17	133.5 (30–588)^*	79.0 (30–1607)	30.0 (30–144)
	IL-23	167.0 (72–405)	240.0 (74–983)	252.0 (9–392)
	FOXP3	311.5 (63–694)^**	135.5 (15–1284)	49.0 (15–252)
	IFN-	45.0 (2.0–249.7)^**	15.7 (1.0–122.2)^*	1.0 (1.0–5.6)
	TNF-	30.9 (8.9–53.4)	23.9 (3.1–111.7)	18.8 (3.4–47.6)

, Mann-Whitney U-test.

International Scholarly Research Notices

In Crohn's Disease, Anti-TNF- 𝜶 Treatment Changes the Balance between Mucosal IL-17, FOXP3, and CD4 Cells

Table 2

In Crohn's Disease, Anti-TNF- Treatment Changes the Balance between Mucosal IL-17, FOXP3, and CD4 Cells